165 Scalp, palmoplantar, and nail involvement in moderate bio-naive psoriasis patients treated with apremilast: 6-week interim results of a real-world, multicenter, prospective study in Greece

Abstract

In this study, we investigated what exposure period to common pollutants and meteorological parameters has the strongest association with eczema severity or probability of admission to hospital with eczema. Using two datasets from an urban population: local eczema patient emergency department (ED) visits (n¼ 1057) and data from a phenotyping study in an immigrant population (n¼363), we looked at the relationship of admission rates, eczema severity and local pollution/weather station data e 10 mm particulate matter (PM10) 2.5 mm

Effectiveness and safety of apremilast in biologic‐naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study

“…26 In APRAISAL, improvements in nail, scalp and palmoplantar psoriasis were noted as soon as W6 and were sustained over time. 27 At W16, approximately half of the patients in APRAISAL who had scalp and palmoplantar involvement at baseline attained ScPGA and PPPGA scores of 0 or 1. These achievement rates are somewhat lower than those seen in the LAPIS-PSO study, in which 69.4% and 83.3% of patients respectively 20 achieved ScPGA and PPPGA scores of 0 or 1 at W16.…”

“…Apremilast has consistently shown improvements in pruritus and psoriasis in special areas in moderate‐to‐severe psoriasis, 5,6,25 moderate psoriasis 4 and moderate‐to‐severe psoriasis of the scalp 26 . In APRAISAL, improvements in nail, scalp and palmoplantar psoriasis were noted as soon as W6 and were sustained over time 27 . At W16, approximately half of the patients in APRAISAL who had scalp and palmoplantar involvement at baseline attained ScPGA and PPPGA scores of 0 or 1.…”